THERAPY DOSSIER · th-10791eaf0db5

Amlodipine plus atorvastatin

Drug · Voltage-gated L-type calcium channel blocker (BLOCKER)

No trauma translation Suggest a correction

Review required. This record is flagged as borderline.

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Voltage-gated L-type calcium channel blocker (BLOCKER)
Target: Voltage-gated L-type calcium channel
Injury models: Other
Reported indication: Amlodipine: hypertension and chronic stable/vasospastic angina (approved 1992); combination (Caduet) adds atorvastatin for dyslipidaemia/CV risk
First approval: 1992
Development stage: Approved antihypertensive/lipid combination; not an acute-injury therapeutic
ChEMBL record: CHEMBL1491 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Amlodipine; Amlodipino; Istin; Norvasc; Astudal 5; HGP-0904
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05275907 ↗PHASE4withdrawn

Blockade of Calcium Channels and Sodium Chloride Cotransporters in Liver Transplant Hypertension

High Blood Pressure · Liver Transplant · Renal Function Abnormal

Enrolment: 0 · Results not recorded

NCT02996916 ↗PHASE4unknown

Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue

Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension

Enrolment: 100 · Results not recorded

NCT02738632 ↗PHASE3completed

Telmisartan/Amlodipine/Hydrochlorothiazide vs Telmisartan/Amlodipine for Essential Hypertension

Essential Hypertension

Enrolment: 300 · Results not recorded

NCT05144360 ↗PHASE3withdrawn

Atenas Association in Treatment of Type II Diabetes Mellitus and Hypertension

Hypertension Associated · Type II Diabetes Mellitus

Enrolment: 0 · Results not recorded

NCT00614380 ↗PHASE3completed

Open Label Follow-up of Telmisartan + Amlodipine in Patients With Hypertension

Hypertension

Enrolment: 976 · Results not recorded

NCT00402103 ↗PHASE3completed

Long-term Safety of Aliskiren 300 mg / Amlodipine 10 mg in Essential Hypertension

Hypertension

Enrolment: 556 · Results not recorded

NCT03897868 ↗PHASE2completed

Dose-Response Study of HCP1803 in Patients With Essential Hypertension

Hypertension

Enrolment: 248 · Results not recorded

NCT01243268 ↗Phase not recordedcompleted

Post-Marketing Surveillance of Twynsta (Telmisartan + Amlodipine) in Korean Hypertensive Patients

Hypertension

Enrolment: 674 · Results not recorded

NCT01499511 ↗Phase not recordedcompleted

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

Hypertension · Diabetes · Death From Cardiovascular Disease · Myocardial Infarction · Stroke

Enrolment: 1718 · Results not recorded

NCT01353274 ↗Phase not recordedcompleted

Survey on Drug Use of Micamlo Combination Tablets AP in Patients With Hypertension

Hypertension

Enrolment: 1157 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21270816 ↗2011Reported benefit

Combination of amlodipine and atorvastatin synergistically reduces leukocyte recruitment to mechanically injured mouse femoral artery.

MouseOtherC57BL/6MaleAmlodipine 0.5 mg/kg/day; atorvastatin 1 mg/kg/dayFor 7 days after injury

Model: Intraluminal wire injury of the femoral artery

Co-administration of low-dose amlodipine and atorvastatin, but not either alone, synergistically inhibited leukocyte recruitment and oxidative stress at the injured artery.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…